hydralazine has been researched along with Renal Insufficiency in 8 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 52-year-old Hispanic woman with a medical history of resistant hypertension treated with hydralazine 10 mg twice daily for 1 year presented with generalized weakness, dizziness, nausea, vomiting, and gross hematuria." | 8.31 | Overlapping drug-induced vasculitis, ANCA-associated vasculitis, and lupus nephritis caused by low-dose hydralazine. ( Agaronov, A; Akhondi, H; Bhatnagar, M; Pepito, D; Sarkisyan, E; Sotoudeh Deilamy, I, 2023) |
| "A 52-year-old Hispanic woman with a medical history of resistant hypertension treated with hydralazine 10 mg twice daily for 1 year presented with generalized weakness, dizziness, nausea, vomiting, and gross hematuria." | 4.31 | Overlapping drug-induced vasculitis, ANCA-associated vasculitis, and lupus nephritis caused by low-dose hydralazine. ( Agaronov, A; Akhondi, H; Bhatnagar, M; Pepito, D; Sarkisyan, E; Sotoudeh Deilamy, I, 2023) |
| "We investigated the role of angiotensin II and endothelin-1 using the angiotensin AT1 receptor antagonist losartan and the endothelin ETA receptor antagonist atrasentan, in malignant hypertension and renal failure and damage induced by nitric oxide (NO) synthase inhibition in Harlan Sprague-Dawley (SD) rats." | 3.75 | Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat. ( Agharazii, M; Bélanger, S; Larivière, R; Lebel, M; Lemieux, P; Therrien, F, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatnagar, M | 1 |
| Agaronov, A | 1 |
| Sarkisyan, E | 1 |
| Sotoudeh Deilamy, I | 1 |
| Pepito, D | 1 |
| Akhondi, H | 1 |
| Bomback, AS | 1 |
| Therrien, F | 1 |
| Lemieux, P | 1 |
| Bélanger, S | 1 |
| Agharazii, M | 1 |
| Lebel, M | 1 |
| Larivière, R | 1 |
| Kawarazaki, H | 1 |
| Ando, K | 1 |
| Nagae, A | 1 |
| Fujita, M | 1 |
| Matsui, H | 1 |
| Fujita, T | 1 |
| Pan, L | 1 |
| Payne, J | 1 |
| Clark, M | 1 |
| MCQUIGGAN, MC | 1 |
| OLIVER, WJ | 1 |
| LITTLER, ER | 1 |
| CERNY, JC | 1 |
| Suganuma, E | 1 |
| Zuo, Y | 1 |
| Ayabe, N | 1 |
| Ma, J | 1 |
| Babaev, VR | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Ichikawa, I | 1 |
| Fogo, AB | 1 |
| Kon, V | 1 |
8 other studies available for hydralazine and Renal Insufficiency
| Article | Year |
|---|---|
Overlapping drug-induced vasculitis, ANCA-associated vasculitis, and lupus nephritis caused by low-dose hydralazine.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2023 |
An Elderly Man with Fatigue, Dyspnea, and Kidney Failure.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopla | 2017 |
Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrasenta | 2009 |
Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Cyclic | 2010 |
Question: does isosorbide dinitrate/hydralazine therapy benefit systolic heart failure patients with renal insufficiency?
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Drug Combinations; Evidence-Based M | 2011 |
HEMOLYTIC UREMIC SYNDROME.
Topics: Acute Kidney Injury; Anemia, Hemolytic; Child; Diagnosis; Dialysis; Diarrhea; Drug Therapy; Glomerul | 1965 |
Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atherosclerosis; Choleste | 2006 |
Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. The Large State Peer Review Organization Consortium.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; | 1997 |